ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
+12.23%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$597M
AUM Growth
+$597M
(+20%)
Cap. Flow
+$37.8M
Cap. Flow
% of AUM
6.34%
Top 10 Holdings %
Top 10 Hldgs %
54.95%
Holding
336
New
84
Increased
76
Reduced
73
Closed
71
Top Buys
| 1 |
Immunovant
IMVT
|
$18.7M |
| 2 |
Ascendis Pharma
ASND
|
$16.4M |
| 3 |
Zura Bio
ZURA
|
$15.3M |
| 4 |
Zai Lab
ZLAB
|
$12.3M |
| 5 |
AAM
AA Mission Acquisition Corp.
AAM
|
$10.1M |
Top Sells
| 1 |
Protagonist Therapeutics
PTGX
|
$28M |
| 2 |
Roivant Sciences
ROIV
|
$13M |
| 3 |
Edgewise Therapeutics
EWTX
|
$11.2M |
| 4 |
Merck
MRK
|
$8.47M |
| 5 |
TECX
Tectonic Therapeutic, Inc. Common Stock
TECX
|
$6.96M |
Sector Composition
| 1 | Healthcare | 88.63% |
| 2 | Financials | 3.75% |
| 3 | Communication Services | 0.59% |
| 4 | Utilities | 0.21% |
| 5 | Technology | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Indivior
INDV
$3.08B
| $527K | 0.09% |
54,057
-15,950
| -23% | -$156K |
|
102
Masimo
MASI
$7.43B
| $519K | 0.08% |
3,894
+3,856
| +10,147% | +$514K |
|
103
Lexeo Therapeutics
LXEO
$266M
| $517K | 0.08% |
57,166
+55,866
| +4,297% | +$505K |
|
104
Target Hospitality
TH
$878M
| $511K | 0.08% |
65,741
-47,885
| -42% | -$373K |
|
105
Taysha Gene Therapies
TSHA
$791M
| $505K | 0.08% |
251,400
+600
| +0.2% | +$1.21K |
|
106
Soleno Therapeutics
SLNO
$3.56B
| $505K | 0.08% |
10,000
-29,929
| -75% | -$1.51M |
|
107
Arvinas
ARVN
$580M
| $502K | 0.08% |
20,400
-12,000
| -37% | -$296K |
|
108
WisdomTree Floating Rate Treasury Fund
USFR
$18.8B
| $502K | 0.08% |
10,000
-43,000
| -81% | -$2.16M |
|
109
Apellis Pharmaceuticals
APLS
$3.51B
| $498K | 0.08% |
17,252
-3,398
| -16% | -$98K |
|
110
VistaGen Therapeutics
VTGN
$113M
| $491K | 0.08% |
+163,078
| New | +$491K |
|
|
111
Edgewise Therapeutics
EWTX
$1.54B
| $485K | 0.08% |
18,178
-418,430
| -96% | -$11.2M |
|
|
BPMC
112
DELISTED
Blueprint Medicines
BPMC
| $472K | 0.08% |
+5,100
| New | +$472K |
|
113
Viking Therapeutics
VKTX
$3.02B
| $450K | 0.07% |
7,100
-84,127
| -92% | -$5.33M |
|
114
TherapeuticsMD
TXMD
$12.7M
| $448K | 0.07% |
270,160
| – | – |
|
115
BiomX
PHGE
$14.1M
| $441K | 0.07% |
+432,700
| New | +$441K |
|
116
Algonquin Power & Utilities
AQN
$4.32B
| $436K | 0.07% |
80,000
+65,000
| +433% | +$354K |
|
117
Movano
MOVE
$7.39M
| $416K | 0.07% |
1,159,826
-247,174
| -18% | -$88.8K |
|
118
Gossamer Bio
GOSS
$587M
| $411K | 0.07% |
416,958
-115,670
| -22% | -$114K |
|
119
CASI Pharmaceuticals
CASI
$36.1M
| $399K | 0.07% |
64,835
+56,595
| +687% | +$349K |
|
|
ADGM
120
Adagio Medical Holdings, Inc Common Stock
ADGM
$25.2M
| $384K | 0.06% |
+148,861
| New | +$384K |
|
|
SAGE
121
DELISTED
Sage Therapeutics
SAGE
| $373K | 0.06% |
+51,650
| New | +$373K |
|
|
CNTA
122
Centessa Pharmaceuticals
CNTA
$2.13B
| $373K | 0.06% |
23,302
-229,895
| -91% | -$3.68M |
|
123
Capricor Therapeutics
CAPR
$287M
| $370K | 0.06% |
+24,307
| New | +$370K |
|
124
Spyre Therapeutics
SYRE
$1.02B
| $369K | 0.06% |
12,560
-22,620
| -64% | -$665K |
|
125
Acadia Pharmaceuticals
ACAD
$4.34B
| $355K | 0.06% |
23,100
+21,800
| +1,677% | +$335K |
|